Introduction: This study assesses the differences in the presentations, complications and metabolic abnormalities of children with renal calyceal microlithiasis (RCM) and overt urolithiasis in different pediatric ages. Materials and Methods: A total of 465 children with urolithiasis were investigated retrospectively. Patients were categorized based on their ages to infancy, early childhood, middle childhood and adolescence. When the hyperechogenic spots on ultrasound imaging were <3 mm, they were considered RCM, and if they were ≥3 mm, they were considered overt urolithiasis. Results: Metabolic abnormalities were detected in 71%; hyperuricosuria in infants, hyperoxaluria in younger children and hypocitraturia in older children were the most common metabolic abnormalities. Hypercalciuria was the only metabolic abnormality that was significantly associated with overt urolithiasis in all pediatric ages (OR 2.25, 95% CI 1.21-4.19). The clinical presentations were not significantly different between RCM and overt urolithiasis; however, complications such as urinary tract infection was significantly higher with overt urolithiasis in infancy (p = 0.01), early childhood (p = 0.02), middle childhood (p = 0.007) and adolescence (p = 0.01). Also, growth retardation was significantly higher with overt urolithiasis in infancy and early childhood (p = 0.02). Conclusions: Most children with urolithiasis have underlying urinary metabolic abnormalities that differ according to the child's age. Despite these differences, hypercalciuria is significantly associated with overt urolithiasis in all pediatric ages. Clinical and laboratory features cannot differentiate RCM and overt urolithiasis; however, complications are significantly higher with overt urolithiasis.

Keywords:
Microcalculi, Children, Nephrolithiasis, Urinary, Urolithiasis, Stone
1.
Dwyer ME, Krambeck AE, Bergstralh EJ, Milliner DS, Lieske JC, Rule AD: Temporal trends in incidence of kidney stones among children: a 25-year population based study. J Urol 2012;188:247-252.
2.
López M, Hoppe B: History, epidemiology and regional diversities of urolithiasis. Pediatr Nephrol 2010;25:49-59.
3.
Baştuğ F, Gündüz Z, Tülpar S, Poyrazoğlu H, Düşünsel R: Urolithiasis in infants: evaluation of risk factors. World J Urol 2013;31:1117-1122.
4.
Wang S, Zhang Y, Mao Z, He X, Zhang Q, Zhang D: A meta-analysis of coffee intake and risk of urolithiasis. Urol Int 2014;93:220-228.
5.
Şirin A, Emre S, Alpay H, Nayir A, Bilge I, Tanman F: Etiology of chronic renal failure in Turkish children. Pediatr Nephrol 1995;9:549-552.
6.
Wang HH, Wiener JS, Lipkin ME, Scales CD Jr, Ross SS, Routh JC: Estimating the nationwide, hospital based economic impact of pediatric urolithiasis. J Urol 2015;193(5 suppl):1855-1859.
7.
La Manna A, Polito C, Cioce F, De Maria G, Capacchione A, Rocco CE, et al: Calyceal microlithiasis in children: report on 196 cases. Pediatr Nephrol 1998;12:214-217.
8.
Escribano J, Balaguer A, Martin R, Feliu A, Espax R: Childhood idiopathic hypercalciuria - clinical significance of renal calyceal microlithiasis and risk of calcium nephrolithiasis. Scand J Urol Nephrol 2004;38:422-426.
9.
Alpay H, Ozen A, Gokce I, Biyikli N: Clinical and metabolic features of urolithiasis and microlithiasis in children. Pediatr Nephrol 2009;24:2203-2209.
10.
Polito C, Cioce F, La Manna A, Maiello R, Di Toro R: Renal calyceal microlithiasis: clinical presentation may precede sonographic evidence. Clin Pediatr (Phila) 1999;38:521-524.
11.
Polito C, Apicella A, Marte A, Signoriello G, La Manna A: Clinical presentation and metabolic features of overt and occult urolithiasis. Pediatr Nephrol 2012;27:101-107.
12.
Bilge I, Yilmaz A, Kayiran SM, Emre S, Kadioglu A, Yekeler E, et al: Clinical importance of renal calyceal microlithiasis in children. Pediatr Int 2013;55:731-736.
13.
Avner ED, Harmon WE, Niaudet P, Yoshikawa N: Pediatric Nephrology, ed 6. Berlin, Springer, 2009.
14.
Elmacı AM, Ece A, Akın F: Pediatric urolithiasis: metabolic risk factors and follow-up results in a Turkish region with endemic stone disease. Urolithiasis 2014;42:421-426.
15.
VanDervoort K, Wiesen J, Frank R, Vento S, Crosby V, Chandra M, et al: Urolithiasis in pediatric patients: a single center study of incidence, clinical presentation and outcome. J Urol 2007;177:2300-2305.
16.
Ubillo-Sánchez JM, Bonilla-Rojas J, Peña LA, Zurita-Cruz JN, Cárdenas-Navarrete R, Serret-Montoya J, et al: [Clinical course and prognosis of patients with urolithiasis in a pediatric hospital]. Rev Med Inst Mex Seguro Soc 2014;52(suppl 2):S68-S73.
17.
Elmacı AM, Ece A, Akın F: Clinical characteristics and metabolic abnormalities in preschool-age children with urolithiasis in southeast Anatolia. J Pediatr Urol 2014;10:495-499.
18.
Landau D, Tovbin D, Shalev H: Pediatric urolithiasis in southern Israel: the role of uricosuria. Pediatr Nephrol 2000;14:1105-1110.
19.
Alaya A, Sakly R, Nouri A, Najjar MF, Belgith M, Jouini R: Idiopathic urolithiasis in Tunisian children: a report of 134 cases. Saudi J Kidney Dis Transpl 2013;24:1055-1061.
20.
Alemzadeh-Ansari MH, Valavi E, Ahmadzadeh A: Predisposing factors for infantile urinary calculus in south-west of Iran. Iran J Kidney Dis 2014;8:53-57.
21.
Madani A, Janatiy SJ, Esfahani ST, Hajizadeh N: Renal calyceal microlithiasis. Acta Med Iran 2005;43:339-341.
22.
Sepahi MA, Heidari A, Shajari A: Clinical manifestations and etiology of renal stones in children less than 14 years age. Saudi J Kidney Dis Transpl 2010;21:181-184.
23.
Kovacevic L, Wolfe-Christensen C, Edwards L, Sadaps M, Lakshmanan Y: From hypercalciuria to hypocitraturia - a shifting trend in pediatric urolithiasis? J Urol 2012;188(4 suppl):1623-1627.
24.
Tefekli A, Esen T, Ziylan O, Erol B, Armagan A, Ander H, et al: Metabolic risk factors in pediatric and adult calcium oxalate urinary stone formers: is there any difference? Urol Int 2003;70:273-277.
25.
Evan AP, Bledsoe SB, Smith SB, Bushinsky DA: Calcium oxalate crystal localization and osteopontin immunostaining in genetic hypercalciuric stone-forming rats. Kidney Int 2004;65:154-161.
26.
Laerum E, Larsen S: Thiazide prophylaxis of urolithiasis. A double-blind study in general practice. Acta Med Scand 1984;215:383-389.
27.
Ettinger B, Citron JT, Livermore B, Dolman LI: Chlorthalidone reduces calcium oxalate calculous recurrence but magnesium hydroxide does not. J Urol 1988;139:679-684.
28.
Frang D, Berényi M, Szebeni R: Prophylaxis of oxalate urolithiasis with alkaline citrates. Ther Hung 1990;38:64-70.
29.
Copelovitch L: Urolithiasis in children: medical approach. Pediatr Clin North Am 2012;59:881-896.
30.
Stapleton FB: Hematuria associated with hypercalciuria and hyperuricosuria: a practical approach. Pediatr Nephrol 1994;8:756-761.
31.
Mohamed J, Riadh M, Abdellatif N: Urolithiasis in infants. Pediatr Surg Int 2007;23:295-299.
32.
Naseri M, Varasteh AR, Alamdaran SA: Metabolic factors associated with urinary calculi in children. Iran J Kidney Dis 2010;4:32-38.
33.
Heyns CF: Urinary tract infection associated with conditions causing urinary tract obstruction and stasis, excluding urolithiasis and neuropathic bladder. World J Urol 2012;30:77-83.
© 2015 S. Karger AG, Basel
2015
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.